Table A3A.

Summary of the PCV7 serotype-specific IgG responses ≥1.0 μg/ml following adjustment for eczema and atopy.

		Adjusted
Vaccine	Unadjusteda	IgE-eczema (at 12 months)	IgE-eczema (ever)	Atopy
PCV7–4	1.30 (0.31, 5.40); p = 0.718	1.30 (0.30, 5.64); p = 0.726	1.28 (0.31, 5.36); p = 0.731	1.50 (0.34, 6.65); p = 0.591
PCV7–6B	2.32 (0.72, 7.41); p = 0.157	2.21 (0.67, 7.27); p = 0.193	2.32 (0.72, 7.41); p = 0.157	2.24 (0.68, 7.40); p = 0.187
PCV7–9V	1.22 (0.36, 4.17); p = 0.754	1.23 (0.35, 4.36); p = 0.752	1.20 (0.35, 4.14); p = 0.776	1.66 (0.44, 6.25); p = 0.456
PCV7–14	1.25 (0.34, 4.64); p = 0.739	1.20 (0.31, 4.63); p = 0.794	1.24 (0.33, 4.62); p = 0.746	1.25 (0.32, 4.82); p = 0.751
PCV7–18C	1.56 (0.24, 10.05); p = 0.643	NA	NA	NA
PCV7–19F	2.62 (0.92, 7.46); p = 0.072	2.32 (0.79, 6.79); p = 0.125	2.61 (0.92, 7.45); p = 0.073	2.49 (0.85, 7.32); p = 0.096
PCV7–23F	2.00 (0.62, 6.46); p = 0.247	2.16 (0.64, 7.32); p = 0.217	1.98 (0.61, 6.47); p = 0.256	2.19 (0.64, 7.43); p = 0.210

Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.

^a Unadjusted analysis after removing missing data for eczema and atopy variables (N = 30 LGG; N = 30 Placebo).